Evoke Pharma Inc. is undergoing a cash merger at a price of $11 per share. This transaction effectively removes the company from the Nasdaq, providing shareholders with a fixed cash consideration. The merger highlights the small market capitalization of Evoke Pharma, which was only $8 million prior to the deal. Investors will receive cash in exchange for their shares, marking a significant exit for current holders.
Company Information
Company
Evoke Pharma
Location
Solana Beach, California, United States
About
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Don't miss Evoke Pharma's next move
Get an email the moment Evoke Pharma makes an acquisition, hires an exec, or expands, usually minutes after it happens.
Solana BeachBiotechnologyHealth CarePharmaceutical